- Home
- CHRO
as 11-15-2024 4:00pm EST
Stocks
Chromocell Therapeutics Corp is a clinical-stage biotechnology company focused on developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain and other associated medical conditions. The company's initial clinical focus is to selectively target the sodium ion-channel known as NaV1.7 for the treatment of various types of chronic neuropathic pain and eye pain. The Company's portfolio also includes pre-clinical work on other sodium channel receptor subtypes, and the company intends to explore these and other compounds for the treatment of additional pain indications.
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | NORTH BRUNSWICK |
| Market Cap: | 3.9M | IPO Year: | 2024 |
| Target Price: | N/A | AVG Volume (30 days): | 100.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -2.20 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.52 - $6.00 | Next Earning Date: | 11-13-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Chromocell Therapeutics Corporation (CHRO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Francis Knuettel II | CHRO | CEO, Pres., CFO, Treas & Secty | Sep 12 '24 | Buy | $0.97 | 5,200 | $5,044.00 | 544,210 | |
| Malamut Richard | CHRO | Director | Sep 12 '24 | Buy | $0.94 | 10,400 | $9,824.88 | 91,565 | |
| Francis Knuettel II | CHRO | CEO, Pres., CFO, Treas & Secty | Sep 10 '24 | Buy | $0.92 | 12,000 | $10,955.00 | 544,210 |
Latest Chromocell Therapeutics Corporation News
CHRO Breaking Stock News: Dive into CHRO Ticker-Specific Updates for Smart Investing
GlobeNewswire
20 days ago
Chromocell Announces Unveiling of Injectable Depot Program for the Treatment of Surgical Pain
GlobeNewswire
21 days ago
Chromocell to Present at Upcoming Fall Investor Conferences
GlobeNewswire
25 days ago
Chromocell Announces Amendment to Stock Repurchase Plan
GlobeNewswire
2 months ago
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
GlobeNewswire
2 months ago
Life Sciences Virtual Investor Forum Agenda Announced for September 19th
GlobeNewswire
2 months ago
Chromocell to Participate in Life Sciences Investor Forum September 19th
GlobeNewswire
2 months ago
Chromocell to Present at the H.C. Wainwright 26th Annual Global Investment Conference
GlobeNewswire
3 months ago
Chromocell Announces Stock Repurchase Plan
Compare CHRO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CHRO Chromocell Therapeutics Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.